Exosens: strong 1H 2026 with record margins, guidance at top of range

Research evidence excerpt

Exosens: strong 1H 2026 with record margins, guidance at top of range

plification division (71% of group) revenue is >95% dependent on defence budgets, which are

by nature highly volatile year-on-year, fluctuating with changes in geopolitical circumstances. Rapid retreats of Western armed

forces from overseas operations (such as the recent Afghanistan withdrawal) or lower perceived geopolitical risk can lead to

sharply lower defence budgets, which may impair the group’s growth prospects. Changes in funding programmes and subsidies

for R&D (that cover 1/3 of the group’s gross R&D expenditure) could lead to materially higher opex at Exosens, hurting its margins.

Customer concentration is high (40% of group revenue with the NVG market leader Theon), leaving the group vulnerable to

sudden, unpredictable changes in customer spending patterns, as well as to leading customers’ component manufacturing in-

sourcing attempts. Trade wars could affect revenue growth prospects in Life Sciences and Industrial control verticals (72% of

Detection and Imaging division, itself 29% of group revenue). Finally, the group has put in place an ambitious bolt-on M&A policy

with the aim to double its revenue base in Detection and Imaging, implying a significant execution risk depending on the quality

of available takeover targets.

RATINGS DEFINITIONS, BENCHMARKS AND DISTRIBUTION

EQUITY RATINGS DEFINITIONS

Bernstein brand

The Bernstein brand rates stocks based on forecasts of relative performance for the next 12 months versus the S&P 500 for

stocks listed on the U.S. and Canadian exchanges, versus the Bloomberg Europe Developed Markets Large and Mid Cap Price

Return Index EUR (EDME) for stocks listed on the European exchanges and emerging markets exchanges outside of the Asia